The in-vitro activity of the triazole antifungal agent voriconazole was compared with itraconazole and amphotericin B against 60 aspergillus isolates. Susceptibility tests were performed using two methods: a macrodilution and a microdulution method. 
Introduction
Invasive aspergillosis is now a common opportunistic fungal infection in immunocompromised patients. 1 In a recent post-mortem study it was found that there had been a significant increase in aspergillus infections during the period 1978-1992. 2 Amphotericin B and itraconazole are currently the only available treatment options for invasive aspergillosis. However, the success rate with amphotericin B is generally poor, and inadequate absorption of itraconazole in AIDS and neutropenic patients can also limit the use of this drug. 3 Voriconazole is a triazole antifungal agent with a broad spectrum of activity against the majority of human fungal pathogens. Voriconazole has been shown to have potent in-vitro activity against Candida spp., 4 filamentous fungi, 5 and dimorphic fungi. 6 It also has clinical activity in patients with both acute and chronic invasive aspergillosis. 7, 8 In this study we investigated the in-vitro activity of voriconazole against a range of Aspergillus species and compared its activity with those of itraconazole and amphotericin B. 
Materials and methods

Strains
Preparation of drugs
Voriconazole (Pfizer, Sandwich, UK) was dissolved in dimethyl sulphoxide (Sigma, Poole, UK) to produce a stock solution of 3200 mg/L. Itraconazole (Janssen Research Foundation, Beerse, Belgium) was suspended in 50% acetone and 50% 0.2 M HCl at a final concentration of 3200 mg/L. The drug preparation was mixed vigorously and heated in a 60°C water bath for 1-2 h until the drug had completely dissolved. Amphotericin B with desoxycholate (Squibb, Hounslow, UK) was dissolved in sterile water to produce a stock solution of 1600 mg/L. All drugs were stored in the dark at 20°C.
Susceptibility testing
Broth macrodilution. RPMI-1640 (Sigma) buffered to pH 7.0 with morpholinopropanesulphonic acid (Sigma) and supplemented with 2% glucose (RPMI) was used to test voriconazole and itraconazole, and Yeast Nitrogen Base (Difco, West Molesey, UK) with 0.5% glucose was used to test amphotericin B. Two-fold dilutions of 1 mL of drug in the appropriate medium were then performed so that the final ranges of drug concentrations were 0.03-16 mg/L for voriconazole and itraconazole and 0.03-32 mg/L for amphotericin B.
The inoculum was prepared by wetting a sterile loop with phosphate-buffered saline (Oxoid, Basingstoke, UK) with 0.05% Tween 80 (Fisons, Loughborough, UK) and transferring a loopful of conidia into 5 mL PBS/ Tween. The suspension was measured using a haemocytometer and diluted in appropriate medium to produce a final concentration of 2 10 3 conidia/mL. One millilitre of the inoculum was added to every tube in the drug dilution series. Positive, negative, and solvent controls were also included. The tubes were incubated at 37°C on a gyratory shaker for 40-42 h. The MIC was read visually and defined as the lowest drug concentration to inhibit growth of the fungus completely.
Minimum fungicidal concentrations (MFCs)
One hundred microlitres was removed from every tube without growth and the last tube to show growth, and pipetted on to horse blood agar. Each sample was allowed to soak into the agar and plates were then streaked and incubated for 48 h at 37°C. The MFC was defined as the lowest drug concentration to yield less than three colonies. This represents 98% killing of the original inoculum.
Broth microdilution
A broth microdilution procedure was also used to test 60 aspergillus isolates against all drugs using RPMI. To prepare the drug dilution series, start solutions of the drugs were made in RPMI and dispensed into the first well of the microtitre tray. Doubling dilutions were then performed to give drug dilutions as previously described. Positive and solvent controls were also included.
The inoculum was obtained as before, although a higher inoculum of 1 19 6 conidia/mL was prepared in RPMI medium. One hundred microlitres of this inoculum was added to each well of the drug dilution series, including the positive and solvent control, so that the final volume in the microtitre plates was 200 L and the final inoculum was 5 10 5 conidia/mL. The plates were incubated in a moist tray at 37°C for 48 h.
Analysis of data
The differences between species were measured using a one-way ANOVA for each of the three drugs for both susceptibility testing methods. A post-hoc test using a Bonferroni correction for multiple tests was used to find which species were statistically significant. Agreement between the two methods was assessed using an intraclass coefficient (ICC) to calculate the proportion of exact agreement (SPSS for Windows).
Results and discussion
The MIC 50 , MIC 90 , and range of MIC results for both susceptibility testing methods are shown in the Table. Voriconazole was found to have good in-vitro activity against a range of Aspergillus species. No cross-resistance was observed between voriconazole and itraconazole. Three A. fumigatus isolates had MICs 16 mg/L of itraconazole; when these were tested with voriconazole, MICs of 0.5-1 mg/L were obtained. These values fell into the range of MICs for all isolates tested with voriconazole. There is currently no standardized reference method for susceptibility testing of filamentous fungi. In this study we used a broth microdilution test that has been shown to detect resistance to itraconazole reliably in vitro and in vivo. 9 A broth macrodilution method was also assessed in this study.
There was no evidence of statistical differences between the species (P 0.24) for voriconazole (excluding A. nidulans (n 2) due to the small group number). The results for all drugs using the microdilution method were found to be higher on average than the values obtained by the macrodilution method. There was moderate agreement between the two methods for voriconazole (ICC 0.41), good agreement for itraconazole (ICC 0.73), and almost no agreement for amphotericin B (ICC 0.05).
Minimum fungicidal concentrations were obtained only with the macrobroth system. The geometric mean (GM) MFC and ranges were 0.63 and 0.125-8 mg/L for voriconazole, 0.38 and 0.06-32 mg/L for itraconazole, and 1.44 and 0.5-32 mg/L for amphotericin B. Minimum fungicidal concentrations using criteria of 98% kill showed voriconazole to be fungicidal for almost all of the isolates tested (96%). This result mirrors those for itraconazole and amphotericin B, in which 95% of isolates tested were killed in vitro within the drug dilution range.
On the basis of these in-vitro results, voriconazole seems to be a promising antifungal agent for the treatment of Aspergillus infections. Further studies are warranted to evaluate the full potential of this drug. Phase II studies in invasive aspergillosis are complete and two large randomized studies are in progress.
